Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The market size of gene therapy involving adeno-associated virus (avv) vectors has seen a quick expansion in the past few years. The market’s value is set to increase from $2.7 billion in 2024 to $3.16 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.7%. Factors driving this growth during the historical period include ramped up investment in gene therapy research, an increased uptake of gene editing technologies, the escalating prevalence of genetic disorders and unresolved healthcare requirements, the burgeoning demand for targeted therapies, and a rise in partnerships among biotech firms and research institutes.

Anticipated to experience significant growth in the upcoming years, the adeno-associated virus (AAV) vectors in gene therapy sector is projected to swell to $6.09 billion by 2029 with a compound annual growth rate (CAGR) of 17.6%. This growth trajectory in the predicted timeframe can be credited to factors such as the progressive developments in AAV capsid engineering, heightened focus on precision medicine, expanding investments in genetic investigation and biotechnology, an uptick in gene therapy clinical examinations and clearances, and a surge in demand for tailored treatments. Key trends to watch out for during this period include the ascension of artificial intelligence in AAV capsid engineering, creation of hybrid AAV vectors capable of handling larger genetic information, advancements in bispecific antibody-mediated AAV guidance, elevation in scalable AAV production and cleaning technology, and emergence of adaptable AAV platforms supporting an array of viral vectors.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp

What Growth-Enabling Forces Are Impacting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The burgeoning interest in gene-oriented treatments is forecasted to drive the expansion of the adeno-associated virus (AAV) vectors in the gene therapy market in the future. Gene-focused therapies are interventions that adjust or control genes to avert, manage, or treat ailments at the genetic level. Progress in genetic studies fuels the growing emphasis on developing gene-oriented therapies, as it improves the accuracy and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy aid in forming gene-focused treatments by securely and efficiently transmitting healing genes into targeted cells, due to their minimal immune response and capability to sustain long-term gene expression. For instance, in 2023, IQVIA, a US-based firm offering cutting-edge analytics and technology solutions for the life sciences sector, reported that global expenditure on cell and gene therapies amounted to $5.9 billion, signifying a 38% rise from the previous year. Hence, the rising emphasis on developing gene-oriented treatments is fuelling the expansion of the adeno-associated virus (AAV) vectors market.

What Are The Main Segment Classifications In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –

1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy

2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Scale of Operation: Preclinical, Clinical, Commercial

4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area

Subsegments:

1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders

2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering

3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

How Are Industry Trends Steering The Expansion Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?

Leading corporations within the adeno-associated virus (AAV) vectors realm in the gene therapy market are concentrating their efforts on progressive innovation, such as customizing vector diversity to augment assay versatility, which in turn magnifies target tissue specificity, augments therapeutic efficacy, and expedites the progression of personal gene therapies throughout diverse indications. Utilizing various AAV serotypes or structures to aid diverse analytical methods and therapeutic applications is what tailored vector diversity for assay versatility signifies. For example, Charles River Laboratories, an American pharmaceutical company, announced the release of new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV) in May 2024. These materials cater to the escalating demands of cell and gene therapy (CGT) advancement. This provision streamlines transitioning from preliminary research to GMP-grade output, standardizing processes and refining uniformity in viral vector production. This introduction addresses a crucial obstacle in amplifying CGT programs for clinical and commercial preparedness.

Which Companies Are Contributing Significantly To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth?

Major companies operating in the adeno-associated virus (AVV) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report

Which Region Holds The Greatest Opportunity For Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Expansion?

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2024. The regions covered in the adeno-associated virus (AVV) vectors in gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24135&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model